Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03347279 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,061
- Enrollment target
- 20
- Study locations
NCT03347279 is a Phase 3 study of Asthma that has completed, run by AstraZeneca. The registered enrollment target is 1,061 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT03347279, a Phase 3 study of Asthma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,061 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Experimental: Tezepelumab
Study Locations (20)
California
- Research Site - Bakersfield
- Research Site - Encinitas
- Research Site - Huntington Beach
- Research Site - Long Beach
- Research Site - Los Angeles
- Research Site - Mission Viejo
- Research Site - Newport Beach
- Research Site - Northridge
- Research Site - Palm Desert
- Research Site - Rolling Hills Estates
- Research Site - Walnut Creek
- Research Site - Westminster
Alabama
- Research Site - Dothan
- Research Site - Foley
Arizona
- Research Site - Gilbert
- Research Site - Tucson
Florida
- Research Site - Celebration
- Research Site - Kissimmee
Colorado
- Research Site - Denver
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,061 participants |
| Start Date | 2017-11-23 |
| Est. Completion | 2020-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03347279
The ClinicalTrials.gov registry entry for NCT03347279 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,061 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (32% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03347279 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03347279 about?
NCT03347279 is a clinical study titled "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma". A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma
What is the current status of trial NCT03347279?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,061 participants. The study started on 2017-11-23. Estimated completion is 2020-11-12.
What conditions does trial NCT03347279 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT03347279?
The interventions under investigation include: Placebo (OTHER), Experimental: Tezepelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03347279?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03347279 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.